Literature DB >> 2021316

Bone marrow and peripheral blood findings in patients with extreme thrombocytosis. A report of 63 cases.

D H Buss1, M L O'Connor, R D Woodruff, F Richards, J K Brockschmidt.   

Abstract

Sixty-three bone marrow (BM) and peripheral blood specimens from patients with platelet counts of 1000 x 10(9)/L or greater were examined in an attempt to determine if any BM or peripheral blood findings could be used reliably to distinguish primary thrombocythemia from other myeloproliferative disorders and extreme examples of reactive thrombocytosis. Our results indicated that the BM findings in primary thrombocythemia were quite similar to those in polycythemia vera and chronic granulocytic leukemia with associated extreme thrombocytosis. However, statistically significant differences between the BM findings in myeloproliferative disorders and extreme reactive thrombocytosis were found in the numbers of megakaryocytes, presence or absence of megakaryocyte clusters, stainable iron, cellularity, and reticulin content. We concluded that BM examination is a useful procedure as an aid in determining the cause of extreme thrombocytosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2021316

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  3 in total

1.  Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts.

Authors:  T Buhr; A Georgii; O Schuppan; A Amor; V Kaloutsi
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

2.  The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states.

Authors:  A W Cashell; D H Buss
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

Review 3.  Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders.

Authors:  Ruben A Mesa
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.